

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]

Final Stakeholder list

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
BeiGene (zanubrutinib)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
African Caribbean Leukaemia TrustAnthony Nolan	 Board of Community Health Councils in Wales
Black Health Agency for Equality	British National Formulary
Blood Cancer UK	Care Quality Commission
Cancer Black Care	Department of Health, Social Services
O	and Public Safety for Northern Ireland
0	Healthcare Improvement Scotland
DIAMO	Medicines and Healthcare products
O (' A II'	Regulatory Agency
Helen Rollason Cancer Charity	
Independent Cancer Patients Voice	,
Kevin Karawa Leukaemia Trust	NHS Confederation Control Madicines Control Minimum
Leukaemia Cancer Society	Scottish Medicines Consortium
Leukaemia Care	Welsh Government
Lymphoma Action	Welsh Health Specialised Services
Macmillan Cancer Support	Committee
Maggie's Centres	Comparator companies
Marie Curie	Comparator companies
South Asian Health Foundation	Accord (bendamustine, cytarabine,
Specialised Healthcare Alliance	doxorubicin)
Tenovus Cancer CareWMUK	 Alliance Healthcare (cyclophosphamide, cytarabine)
	Baxter Healthcare (cyclophosphamide, doxorubicin)
Healthcare professional groups	Celltrion Healthcare (rituximab)
Association of Cancer Physicians	Consilient Health (bendamustine)
British Geriatrics Society	` '
British Institute of Radiology	 Dr. Reddy's Laboratories (bendamustine)
British Oncology Pharmacy	,
Association	Gilead Sciences (brexucabtagene autolousel)
British Psychosocial Oncology Society	autoleucel)
British Society for Haematology	Hospira UK (cytarabine, vincristine)
	Jazz Pharmaceuticals (cytarabine)

Final stakeholder list for the evaluation of zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Society of Interventional Radiology British Transplantation Society Cancer Research UK NHS Blood and Transplant Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Cutaneous Lymphoma Group UK Oncology Nursing Society Others Department of Health and Social Care NHS England 	 Johnson & Johnson Innovative Medicine (ibrutinib) medac GmbH (doxorubicin) Pfizer (cytarabine, doxorubicin, rituximab, vincristine) Roche Products (rituximab) Sandoz (cyclophosphamide, rituximab) Seacross Pharmaceuticals (bendamustine, doxorubicin) Teva UK (vincristine) Zentiva (bendamustine) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England Institute of Cancer Research Leukaemia Busters Leukaemia UK Lymphoma Research Trust MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups
	Public Health WalesUK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient

Final stakeholder list for the evaluation of zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]

Issue date: October 2024



organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.